BioTech Social Media and Updates

Microscopic Robot Delivers Targeted Drugs Inside Bloodstream
SocialMar 25, 2026

Microscopic Robot Delivers Targeted Drugs Inside Bloodstream

Microscopic #Robot Navigates the Bloodstream to Deliver Targeted Medication by @CeoImed #MedTech #Healthcare #HealthTech #Tech #Technology https://t.co/LBJeDdwTuq

By Ron van Loon
Open Review Flags Flaws in Telomere‑river Longevity Study
SocialMar 25, 2026

Open Review Flags Flaws in Telomere‑river Longevity Study

The incredible study using "Rivers of telomeres" to rejuvenate tissues and extend lifespan in mice is now undergoing open peer-review. I did a review, pointing out issues with the methods and the lifespan curves. They're looking for more reviewers. https://t.co/KOiR4F85sT

By João Pedro de Magalhães, PhD
Open-Source DIY Guide to Building mRNA Vaccines
SocialMar 25, 2026

Open-Source DIY Guide to Building mRNA Vaccines

Inspired by the man who built a personalized cancer vaccine for his dog, I’ve written an open-source guide to DIY mRNA vaccine production: philfung.github.io/openvaxx Drawing on my background in running lab startups, the guide covers the entire process - from sequencing...

By Philip Fung
Blueprint for Affordable, Accessible AAV Gene Therapy
SocialMar 25, 2026

Blueprint for Affordable, Accessible AAV Gene Therapy

When people ask "How can we make #AAV #GeneTherapy accessible and affordable" --> this is how 👇

By Nicole Paulk
New Review Links Β‑cell Stress to Type 1 Diabetes
SocialMar 25, 2026

New Review Links Β‑cell Stress to Type 1 Diabetes

Rethinking why the pancreas β-cells become vulnerable to autoimmune attack, leading to Type 1 diabetes. An illuminating review with ideas to counter β-cell stress @ScienceTM https://t.co/zn6a6wEg7u https://t.co/BV0LYnWRNL

By Eric Topol
Summit Sparks Breakthroughs: AI, Gene Therapy, CRISPR, mRNA
SocialMar 25, 2026

Summit Sparks Breakthroughs: AI, Gene Therapy, CRISPR, mRNA

One thing that really makes the in-person summits we run at STAT so amazing: the people in the room. Here's what happened when we asked some of them for the last big breakthrough they saw. Featuring: the infectious @DrBlytheAdamson, genomcis pioneer...

By Matthew Herper
Escitalopram Yields -16.6 HAM‑D Drop After 8 Weeks
SocialMar 25, 2026

Escitalopram Yields -16.6 HAM‑D Drop After 8 Weeks

Anyone have a PDF of this? Perhaps there isn't a digital copy... This one showed an impressive -16.6 HAM-D drop with 8 weeks of escitalopram. It would be good to know their methodology. https://t.co/P5GCYcbxjk

By Robin Carhart‑Harris, PhD
Curiosity Fuels AGI: Autonomous Labs Powered by GPT‑5
SocialMar 25, 2026

Curiosity Fuels AGI: Autonomous Labs Powered by GPT‑5

Awesome being on the @Sequoia Training Data podcast with @gradypb and @sonyatweetybird. Topic links in the 🧵 The most human part of intelligence is curiosity, and science is formalized curiosity. If we want AGI — doing the work of science is...

By Jason Kelly
Bridging Virtual Cells to Real Patients: The Next Frontier
SocialMar 25, 2026

Bridging Virtual Cells to Real Patients: The Next Frontier

Virtual biology burst onto the scene a few years ago. The idea was simple. Model the cell well enough, and you can predict biology before you test it. Large pharma has been thinking about this longer than most. PK/PD models, systems biology,...

By John Cumbers
FDA Clears Denali's AVLAYAH, 91% CSF
SocialMar 25, 2026

FDA Clears Denali's AVLAYAH, 91% CSF

FDA clears Denali's AVLAYAH (macro), 91% CSF HS drop and analysts lift estimates (key). Risk: COMPASS confirmatory readout, infusion reactions. Trade: buy DNLI on 50‑day pullback 🚀 — Viktor Kopylov, PhD, CFA More insights: t.me/si14Kopylov

By Viktor Kopylov, PhD, CFA
Morgan Stanley Sets $20 Target, 120% Upside for IMMX
SocialMar 25, 2026

Morgan Stanley Sets $20 Target, 120% Upside for IMMX

$IMMX - Morgan Stanley initiates coverage with a $20 PT and an outperform rating, implying ~120% upside. https://t.co/Pd4uIH5BkI

By BowTiedBiotech
Pharma AI Shifts From Cloud to On‑Device
SocialMar 25, 2026

Pharma AI Shifts From Cloud to On‑Device

Most AI companies believe the future is cloud-first. Pharma is different. In this industry, data is the kingdom. Experimental data. Molecular designs. Clinical insights. Some of the most valuable intellectual property on Earth. And in many cases, it cannot leave the lab. This is where the typical...

By Alex Zhavoronkov, PhD
Engineered Immune Cells Target Refractory Myeloma, Broader Cancer Potential
SocialMar 25, 2026

Engineered Immune Cells Target Refractory Myeloma, Broader Cancer Potential

Steady progress towards engineering immune cells in the body now for refractory myeloma , with major implications for many autoimmune diseases and cancers https://t.co/K3IksrCFlg https://t.co/1AQ5rLuH1g

By Eric Topol
CEO Amy Burroughs Discusses M&A Post‑ASH25 Data
SocialMar 25, 2026

CEO Amy Burroughs Discusses M&A Post‑ASH25 Data

I asked $TERN CEO Amy Burroughs right after the #ASH25 data was out how she felt about M&A. Congrats to her and her team. https://t.co/2HemPoiqWO

By Brad Loncar
Thousands of P-Values, only a Handful Are Real
SocialMar 25, 2026

Thousands of P-Values, only a Handful Are Real

1/ You ran 20,000 differential expression tests. 1,000 genes came back with p < 0.05. How many are real? Maybe 50. Maybe fewer. Most bioinformaticians learn p-values in stats class. Almost nobody learns why they break at scale. Let me explain: https://t.co/btC71ABX5N

By Ming Tang
MRK Likely to Rerun TERN Study for Data
SocialMar 25, 2026

MRK Likely to Rerun TERN Study for Data

Based on previous form $MRK will probably now rerun the $TERN study, just to prove to itself that the data were real.

By Jacob Plieth
TERN's Termination Terms Hint MRK Could Be Outbid
SocialMar 25, 2026

TERN's Termination Terms Hint MRK Could Be Outbid

For those wondering if $MRK might be outbid, here are the deal termination terms from $TERN https://t.co/TbM3rWyEoG

By Jacob Plieth
Merck Spends $6.7B on CML Drug Despite Gleevec Era
SocialMar 25, 2026

Merck Spends $6.7B on CML Drug Despite Gleevec Era

It's amazing that 25 years after Gleevec we are still watching drug companies pay billions for new drugs for CML. And that, in Adam's previous story, a once deadly cancer was referred to as a chronic disease. Anyway, $MRK buys $TERN...

By Matthew Herper
Amy Burrough
SocialMar 25, 2026

Amy Burrough

Adding $TERN to this list (Merck $6.7B reported) led by Amy Burroughs. Congrats to Amy and team 💪 https://t.co/KZ8CtA2GA0?

By Daphne Zohar
AVXL Withdraws Alzheimer's Drug From EMA After Rejection
SocialMar 25, 2026

AVXL Withdraws Alzheimer's Drug From EMA After Rejection

$AVXL pulled its blarcamesine Alzheimer's application from the EMA after regulators there said there was no fking way it was going to approve a drug that does not work.

By Adam Feuerstein
Novo
SocialMar 25, 2026

Novo

$NVO triple G drug at 2.16 A1c reduction at only week 24 vs a lower 1.9 A1c reduction at a longer 40 weeks for the max dose of the $LLY triple G. But Novo has no pipeline…? 🤷🏻‍♂️ https://t.co/CFcnGZGMqt

By Adam May
Hybrid PandaOmics‑Lobster Platform Accelerates Disease Target Discovery
SocialMar 25, 2026

Hybrid PandaOmics‑Lobster Platform Accelerates Disease Target Discovery

PandaOmics and Lobster hybrid for novel target discovery and disease hypothesis research. @steipete will have serious impact on human life

By Alex Zhavoronkov, PhD
CRBIOTECH's 2025 Impact Projected to Surge Significantly
SocialMar 25, 2026

CRBIOTECH's 2025 Impact Projected to Surge Significantly

📈 The projected 2025 impact of Current Research in Biotechnology is notably higher 🔗https://t.co/HTlbLhpaRc 🌐 #CRBIOTECH #Research #Science https://t.co/DOBMVCJUgC

By Atanas G. Atanasov, PhD
D+Q Senolytic Linked to Brain Demyelination, Prompting Safety Concerns
SocialMar 25, 2026

D+Q Senolytic Linked to Brain Demyelination, Prompting Safety Concerns

The recent study showing D+Q causes demyelination in brain cells leads to more questions than it answers: (I only read the abstract cause paper new & paywalled.) D+Q has been used a lot in mice & humans. Why hasn't this been noticed...

By Karl Pfleger, PhD
Lyme Disease Isn’t a Bioweapon, Says Immunology Researcher
SocialMar 25, 2026

Lyme Disease Isn’t a Bioweapon, Says Immunology Researcher

Since Lyme Disease is suddenly getting more attention than usual: Hi! I’m a researcher and scientist getting my PhD in Immunology, Infection and Epidemiology. I’ve been studying tick feeding and Lyme Disease for over 5 years now looking for an anti-tick...

By Jacquie B | The Sleepiest Scientist
Seeking Enzymes that Decolorize Anthocyanins Like Carotenoid Cleavers
SocialMar 25, 2026

Seeking Enzymes that Decolorize Anthocyanins Like Carotenoid Cleavers

Are there enzymes that cleave anthocyanins into colorless bits? I know there are carotenoid cleavage enzymes that can bite various parts of the saturated chain, but never heard of anthocyaninases... https://t.co/rUHXDWkWvc

By Sebastian Cocioba
Patience Wins: Wait for Maintenance Data, Not Hype
SocialMar 24, 2026

Patience Wins: Wait for Maintenance Data, Not Hype

$ABVX degen traders dumping the stock on a CNBC article saying exactly what I’ve been saying since the trial hit back in July, and what was already blatantly obvious from the earnings release yesterday. WAITING FOR MAINTENANCE DATA is...

By Adam May
SWIFT-Seq Maps Single-Cell Transcriptomes of Myeloma CTCs
SocialMar 24, 2026

SWIFT-Seq Maps Single-Cell Transcriptomes of Myeloma CTCs

SWIFT-seq enables comprehensive single-cell transcriptomic profiling of CTCs in multiple myeloma & precursors [Aug 8, 2025] Lightbody, @RomanosSP et al. @IrenemGhobrial - @LabGhobrial @NatureCancer https://t.co/LhqmRShFo9 #mmsm #LiquidBiopsy #cactc THREAD: https://t.co/87VZtDNy80 https://t.co/41MRROCXwI

By Mike Thompson, MD PhD
Sex‑specific Epigenetic Network Drives Cholesterol and Atherosclerosis
SocialMar 24, 2026

Sex‑specific Epigenetic Network Drives Cholesterol and Atherosclerosis

Sex-specific KDM6A-HNF4A-CREBH network controls lipoprotein cholesterol metabolism and atherosclerosis via epigenetic reprograming of hepatocytes https://t.co/2XpUt6ndcs https://t.co/r5DvCeGMeS

By Ming Tang
Focus on Fundamentals, Not Every New Sequencing Method
SocialMar 24, 2026

Focus on Fundamentals, Not Every New Sequencing Method

1/ I used to panic every time a new *Seq method dropped. ATAC-seq, CUT&Tag, scNOMe-seq, SHARE-seq... the list never ends. I tried to learn them all. I burned out. Here's what I wish someone told me earlier. https://t.co/xUlsvXmaQh

By Ming Tang
New AD Combos Outpace Dupilumab, Injection Frequency Drops
SocialMar 24, 2026

New AD Combos Outpace Dupilumab, Injection Frequency Drops

Atopic dermatitis landscape from Wedbush. Looks like there are two parallel vectors: lower injection frequency ( $APGE ) and combining new mechanisms with IL13/IL4R. So far $JNJ's IL13+IL31 failed (the only one to be directly compared to dupi) while $PFE's...

By Ohad Hammer
Patented Chemo Reform Boosted Profits, Not Patient Benefits
SocialMar 24, 2026

Patented Chemo Reform Boosted Profits, Not Patient Benefits

Please. This is nonsense. You figured out a way to swap castor oil for albumin making it easier to administer paclitaxel, a standard chemotherapy. Same side effects. Look at the label. The best thing you did, for you, was secure...

By Adam Feuerstein
Aging May Be Reversible by Restoring Cellular Information
SocialMar 24, 2026

Aging May Be Reversible by Restoring Cellular Information

It’s not often that a theory about aging feels this transformative. I recently came across research suggesting that aging may not be permanent damage — but a loss of biological information inside our cells. Think of it like a scratched CD. The data...

By Pascal Bornet
AI-Driven Partnership Targets Unmet Gynecological Diseases
SocialMar 24, 2026

AI-Driven Partnership Targets Unmet Gynecological Diseases

We are very happy to join forces together with the wonderful ASKA to go after Novel Targets for Women's Health. Gynecological diseases have long posed challenges, including difficult diagnosis, limited treatment options, and a substantial disease burden, affecting millions of...

By Alex Zhavoronkov, PhD
P‑tau217 Predicts Dementia Risk with Combined Hormone Therapy
SocialMar 24, 2026

P‑tau217 Predicts Dementia Risk with Combined Hormone Therapy

Blood levels of the Alzheimer's biomarker p-tau217 may help identify which women are more vulnerable to dementia when using combined hormone therapy after menopause, while estrogen-only therapy does not show the same association. menopause

By Phys.org Threads
Direct Immune Cell Injection Eradicates Multiple Mouse Cancers
SocialMar 24, 2026

Direct Immune Cell Injection Eradicates Multiple Mouse Cancers

A potentially game-changing discovery by @UCSF's Justin Eyquem @j_eyquem & colleagues – injecting cancer-fighting immune cells directly into the body kills several types of cancers in mice. Paper in @Nature: https://t.co/EXbsfx7whl Summary/video by UCSF: https://t.co/qLYXXvEDTV

By Robert (Bob) Wachter, MD
Doctors Endorse Peptides as Effective and Favorable
SocialMar 24, 2026

Doctors Endorse Peptides as Effective and Favorable

Meanwhile: Anecdotal data: "I spoke lots of doctors, they all said peptides are great and they like them"

By Vishal Gulati
Keyboard Shortcuts Let You Reposition Plasmid Origins Instantly
SocialMar 23, 2026

Keyboard Shortcuts Let You Reposition Plasmid Origins Instantly

I love this so much lololol You can use the arrow keys to circularly permute the plasmid to shift the reference origin as you please, you can use . and , to adjust the circularity of the...

By Sebastian Cocioba
Vibecoding Peaks Between PCRs, Meeting at 9
SocialMar 23, 2026

Vibecoding Peaks Between PCRs, Meeting at 9

Vibecoding between PCR's has hit an all time high. See you at 9pm, Claude. https://t.co/8mJv5GJIut

By Sebastian Cocioba
ABVX Hires Entyvio Creator, Silencing CCO Doubts
SocialMar 23, 2026

ABVX Hires Entyvio Creator, Silencing CCO Doubts

$ABVX panicans were worried about a CCO hire and the company just went out & got the dude who launched Entyvio. Let's go! 🔥🔥🔥

By Adam May
Brief 5‑MeO‑DMT Trip Yields Month‑Long Antidepressant Boost
SocialMar 23, 2026

Brief 5‑MeO‑DMT Trip Yields Month‑Long Antidepressant Boost

One of the most remarkable things about 5-meo-DMT as an antidepressant is that the psychoactive experience is so brief. 10 minute peak, perhaps. 20 min total. And people seldom remember it well. Yet it has possibly the largest anti-depressant effect...

By Ramez Naam
Cyborg Organoids Sense Glucose, Release Hormones for Diabetes
SocialMar 23, 2026

Cyborg Organoids Sense Glucose, Release Hormones for Diabetes

Bioengineers embedded soft, stretchable electronics into the tiny clusters to create “cyborg” organoids. These can mimic the pancreas, sensing glucose levels and releasing hormones. They could help build replacement cells for people with type 1 diabetes. https://spectrum.ieee.org/cyborg-stem-cell-therapy-for-diabetes

By IEEE Spectrum Threads
AI and Genomics Target Aging to Combat Chronic Disease
SocialMar 23, 2026

AI and Genomics Target Aging to Combat Chronic Disease

Aging underpins most chronic diseases and remains the biggest challenge to human health. Thank you @carninci for the opportunity to present @humantechnopole on aging, genomics and AI approaches to identify longevity targets and drugs. https://t.co/ysDGHfJeY0

By João Pedro de Magalhães, PhD
Fermented Cordyceps Broth Improves Primary Insomnia in Trial
SocialMar 23, 2026

Fermented Cordyceps Broth Improves Primary Insomnia in Trial

Effectiveness of fermentation broth of Cordyceps sinensis for primary insomnia: a randomized clinical trial with digital health tool https://t.co/g5iOuzkctO

By Michael Lustgarten, PhD
Reagent Spend Under 5%—Biotech Must Address Cost Gap
SocialMar 23, 2026

Reagent Spend Under 5%—Biotech Must Address Cost Gap

The thing to look at in biotech is your reagent costs as a % of your total research spending - inclusive of lab space, EHS, equipment maintenance, lab labor costs, etc. Lab data is the concrete output of biotech...

By Jason Kelly
Consumer Longevity Research Gains Momentum with Ginkgo Cloud Lab
SocialMar 23, 2026

Consumer Longevity Research Gains Momentum with Ginkgo Cloud Lab

Really excited about the use of @Ginkgo Cloud Lab for consumers to do research in longevity and other consumer apps. These areas are less well-studied than you'd expect as US research funding is largely oriented towards disease. Fun chatting with @LongevityTech about...

By Jason Kelly
US Patients Access Zegfrovy via Apex Oncology
SocialMar 23, 2026

US Patients Access Zegfrovy via Apex Oncology

Another win for Dizal, but how do US patients get hold of Zegfrovy? Via @ApexOnco -> https://t.co/4GVjyHS9vz https://t.co/bjjrnZkNL6

By Jacob Plieth
Pfizer's Lyme Vaccine Data Remains Ambiguous, FDA Review Looms
SocialMar 23, 2026

Pfizer's Lyme Vaccine Data Remains Ambiguous, FDA Review Looms

As someone who lived in Vermont and still spends the summer there, it's disappointing to see the ambiguity in Pfizer's data on a new Lyme disease vaccine. It's a serious threat. Now we can move on to speculating on the...

By John Carroll
Thymus Gland Emerges as Key to Healthy Aging
SocialMar 23, 2026

Thymus Gland Emerges as Key to Healthy Aging

Don't take the time to read about the new landmark studies that put our thymus gland at center stage for healthy aging https://t.co/ENhIn2A2l3 https://t.co/oY2PLSenmf

By Eric Topol